AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. We take a unique pan-antigenic approach for our cancer vaccine — targeting all neoantigens, rather than a select few — allowing our treatment to overcome cancer’s tendency to mutate over time. Utilizing our autologous cell therapy platform, which has generated multiple therapeutic vaccine programs shown to be safe and effective in early clinical trials, we are developing a personalized multi-pathogen vaccine for with adaptive immunity against infectious disease. Our patient-specific treatments in cancer have shown significant promise in eradicating tumors without harmful side effects in our melanoma, glioblastoma and ovarian cancer clinical studies. Our personalized vaccine for COVID-19 demonstrated a 97% T-cell response against the most current strains.